Security Snapshot

FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX) Institutional Ownership

CUSIP: 35473P520

13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

6

Shares (Excl. Options)

51,026

Price

$33.06

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+34,136
Value change
+$1,124,830
Number of holders
6
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$39.73
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • HELX - FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF is tracked under CUSIP 35473P520.
  • 6 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 5 to 6 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $613,283 to $1,686,651.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 6 institutions filings for Q1 2026.

Open SEC evidence

Security key

35473P520

Latest holder period

Q1 2026

13F holders

6

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 6 institutional investors reported holding 51,026 shares of FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
25
Latest
Q1 2026
Rows shown
1-25 of 25
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 51,026 $1,686,651 +$1,124,830 $33.06 6
2025 Q4 16,890 $613,283 +$97,401 $36.31 5
2025 Q3 14,268 $439,474 -$2,212,624 $30.95 5
2025 Q2 92,632 $2,566,990 +$309,093 $27.71 7
2025 Q1 81,687 $2,205,710 -$638,049 $27.00 8
2024 Q4 103,040 $2,973,164 +$1,597,330 $28.85 8
2024 Q3 47,673 $1,545,263 -$962,871 $32.41 5
2024 Q2 78,142 $2,475,997 -$568,500 $31.68 7
2024 Q1 95,001 $3,112,326 -$1,496,883 $32.76 10
2023 Q4 140,810 $4,290,918 +$3,127,647 $30.47 9
2023 Q3 38,719 $1,096,611 -$1,319,967 $28.34 7
2023 Q2 82,302 $2,487,571 -$37,725 $30.23 7
2023 Q1 38,766 $1,177,374 -$121,596 $30.38 6
2022 Q4 42,786 $1,289,178 +$61,903 $30.13 9
2022 Q3 40,724 $1,207,000 +$314,642 $29.63 9
2022 Q2 30,115 $964,000 -$80,086 $32.02 8
2022 Q1 31,478 $1,163,504 -$4,705,792 $36.95 8
2021 Q4 155,206 $7,526,219 -$6,279,460 $48.42 11
2021 Q3 273,604 $14,313,683 +$10,169,162 $52.30 10
2021 Q2 79,619 $4,122,950 -$98,463 $51.79 9
2021 Q1 81,510 $3,532,751 +$1,386,138 $43.35 8
2020 Q4 43,257 $1,916,000 +$761,000 $44.29 5
2020 Q3 28,241 $991,000 -$1,290,500 $35.10 5
2020 Q2 65,000 $2,229,000 -$342,923 $34.29 1
2020 Q1 75,000 $1,678,000 +$1,678,000 $22.37 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .